Sulthiame add‐on therapy for epilepsy
Referencias
Additional references
Bast T, Volp A, Wolf C, Rating D, Sulthiame Study Group. The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTs). Epilepsia 2003;44:215‐20.
Ben‐Zeev B, Watemberg N, Lerman P, Barash I, Brand N, Lerman‐Sagie T. Sulthiame in childhood epilepsy. Paediatrics International 2004;46:521‐4.
Brodie MJ, Dichter MA. Antiepileptic drugs. New England Journal of Medicine 1996;334:168‐75.
Chahem J, Bauer J. Treatment of epilepsy with third‐line antiepileptic drugs. Felbamate, tiagabine, and sulthiame. Der Nervenarzt 2007;78:1407‐12.
Engler F, Maeder‐Ingvar M, Roulet E, Deonna T. Treatment with sulthiame (ospolot) in benign partial epilepsy of childhood and related syndromes: an open clinical and EEG study. Neuropediatrics 2003;34:105‐9.
[No authors listed]. ILAE Commission Report. The epidemiology of the epilepsies: future directions. International League Against Epilepsy. Epilepsia 1997;38:615‐8.
Go T. Effect of antiepileptic drug polytherapy on crystalluria. Paediatric Neurology 2005;32:113‐5.
Gross‐Selbeck G. Current treatment strategies for seizures and in epilepsy in children. Monatsschrift fur Kinderheilkunde 2001;149:1174‐9.
Koepp MJ, Patsalos PN, Sander JWAS. Sulthiame in adults with refractory epilepsy and learning disability: an open trial. Epilepsy Research 2002;50:277‐82.
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org.
Leniger T, Wiemann M, Bingmann D, Widman G, Hufnagel A, Bonnet U. Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. Epilepsia 2002;43:469‐74.
Livingston S, Villamater C, Sakata Y. Ospolot (sulthiame) in epilepsy. Diseases of the Nervous System 1967;28:259‐63.
Miyajima T, Kumada T, Kimura N, Mikuni T, Fujii T. Sulthiame treatment for patients with intractable epilepsy. No To Hattatsu 2009;41:17‐20.
Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Sulthiame Study Group. Epilepsia 2000;41:1284‐8.
Sander JWAS. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993;34:1007‐16.
Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy: a reappraisal. CNS Drugs 1995;3:194‐208.
Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration.
Weissbach A, Tirosh I, Scheuerman O, Hoffer V, Garty BZ. Respiratory alkalosis and metabolic acidosis in a child treated with sulthiame. Pediatric Emergency Care 2010;26:752‐3.
Epilepsy: aetiology, epidemiology and prognosis. World Health Organization2001.
Wirrel E, Sherman EMS, Vanmastrigt R, Hamiwka L. Deterioration in cognitive function in children with benign epilepsy of childhood with central temporal spikes treated with sulthiame. Journal of Child Neurology 2008;23:14‐21.
